UPCC 04717: Phase I open label dose-escalation study to evaluate the safety expansion persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor) administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)

The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days after the administration of UCART19) and the overall response during the study period.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  ['B-cell Acute Lymphoblastic Leukemia']
• Age: - 99 Years
• Gender: All